Tags: convertible , pharmaceuticals

Equities

Drug maker United Laboratories sells $125 million of CBs

United Labs' renminbi-denominated convertible bond comes at attractive terms, but still falls below par.

By Anette Jönsson | 8 November 2011

Equities

Repeat Indian issuer brings $250 million CB

Sterling Biotech prices wide after demand is described as healthy but price sensitive.

By Anette Jönsson | 20 April 2007

Equities

Orchid CB receives brutal treatment in the secondary market

A hefty increase in the deal size and concern about the use of proceeds push the bond price sharply below par.

By Anette Jönsson | 16 February 2007

Equities

Upsized CB for Indian drug maker

Orchid Chemicals raises $175 million to grow its portfolio of drugs. Conversion premium set at 30%.

By Anette Jönsson | 13 February 2007

Equities

Jubilant Organosys sells $200 million CB while pondering possible acquisition

Issue marks seventh CB from an Indian pharmaceutical company since December; conversion premiums still high.

By Anette Jönsson | 25 April 2006

Equities

Aurobindo Pharma CB uses rare premium structure

Strong expansion story allows company to fix conversion price on 25% of the deal in 12 months time; investors compensated by high yield and high bond floor.

By Anette Jönsson | 23 April 2006

Equities	Debt
M&A	Moves People Moves Business Moves
News & Views View Point Macro & Markets Corporate	Banking Structured Products FX Private Banking
Editor's Desk Awards Co-published Editor's Desk Polls Book Review Private Capital	Conference Highlights
CorporateTreasury Cash Trade CorporateTreasury Moves Risk	Magazine Highlights

Tags: convertible, pharmaceuticals

Tags: convertible , pharmaceuticals